--- title: "Brokers Set Expectations for C4 Therapeutics Q3 Earnings" type: "News" locale: "en" url: "https://longbridge.com/en/news/295788075.md" description: "Brookline Capital Markets raised its Q3 2026 EPS estimate for C4 Therapeutics (NASDAQ:CCCC) to ($0.20) from ($0.21). Weiss Ratings restated a 'sell' rating, while the consensus remains 'Moderate Buy' with an average target price of $7.75. Recent institutional activity includes Renaissance Technologies increasing its stake by 53.6%. The company recently reported Q2 earnings beating estimates, with revenue of $6.64 million." datetime: "2026-08-13T11:13:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295788075.md) - [en](https://longbridge.com/en/news/295788075.md) - [zh-HK](https://longbridge.com/zh-HK/news/295788075.md) generator: "portal-rs" --- # Brokers Set Expectations for C4 Therapeutics Q3 Earnings - MarketBeat Week in Review – 12/18 - 12/22 C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Equities research analysts at Brookline Capital Markets boosted their Q3 2026 earnings per share (EPS) estimates for C4 Therapeutics in a research note issued on Tuesday, August 11th. Brookline Capital Markets analyst L. Cann now expects that the company will earn ($0.20) per share for the quarter, up from their previous estimate of ($0.21). The consensus estimate for C4 Therapeutics' current full-year earnings is ($0.87) per share. Brookline Capital Markets also issued estimates for C4 Therapeutics' FY2026 earnings at ($0.80) EPS, FY2027 earnings at ($0.93) EPS and FY2028 earnings at ($1.64) EPS. Get **C4 Therapeutics** alerts: Separately, Weiss Ratings restated a "sell (d-)" rating on shares of C4 Therapeutics in a research report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $7.75. - C4 Therapeutics blasts off: what's next? **Check Out Our Latest Report on CCCC** ## C4 Therapeutics Stock Up 0.8% Shares of NASDAQ CCCC opened at $3.90 on Thursday. The company has a market cap of $431.22 million, a P/E ratio of -3.90 and a beta of 2.91. C4 Therapeutics has a 52 week low of $1.69 and a 52 week high of $5.17. The business has a 50-day simple moving average of $3.90 and a two-hundred day simple moving average of $3.17. C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. The firm had revenue of $6.64 million for the quarter, compared to analysts' expectations of $4.00 million. C4 Therapeutics had a negative return on equity of 47.15% and a negative net margin of 289.44%. ## Institutional Trading of C4 Therapeutics Hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its holdings in C4 Therapeutics by 53.6% during the 1st quarter. Renaissance Technologies LLC now owns 2,461,815 shares of the company's stock valued at $6,475,000 after buying an additional 859,235 shares during the last quarter. Stempoint Capital LP bought a new stake in C4 Therapeutics in the 1st quarter worth $1,192,000. Wasatch Advisors LP increased its position in shares of C4 Therapeutics by 18.9% in the second quarter. Wasatch Advisors LP now owns 3,522,644 shares of the company's stock valued at $16,451,000 after acquiring an additional 560,883 shares during the period. Seven Fleet Capital Management LP bought a new position in shares of C4 Therapeutics during the first quarter valued at about $150,000. Finally, Sei Investments Co. purchased a new stake in shares of C4 Therapeutics during the first quarter worth about $66,000. Institutional investors own 78.81% of the company's stock. ## About C4 Therapeutics (Get Free Report) C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body's natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies. The company's pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages. ## Read More - Five stocks we like better than C4 Therapeutics - GE Vernova’s AI Power Boom Faces a Profit Test - Cardinal Health Earnings: Can Perfection Get Priced In Twice? - Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand - Legacy Jet Builders Stall While Embraer Accelerates to New Highs *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in C4 Therapeutics Right Now? Before you consider C4 Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and C4 Therapeutics wasn't on the list. While C4 Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [CCCC.US](https://longbridge.com/en/quote/CCCC.US.md) - [SEIC.US](https://longbridge.com/en/quote/SEIC.US.md) - [GEV.US](https://longbridge.com/en/quote/GEV.US.md) - [CAH.US](https://longbridge.com/en/quote/CAH.US.md) - [NBIS.US](https://longbridge.com/en/quote/NBIS.US.md) - [ERJ.US](https://longbridge.com/en/quote/ERJ.US.md) - [EMBJ.US](https://longbridge.com/en/quote/EMBJ.US.md) ## Related News & Research - [C4 Therapeutics Q2 revenue beats estimates, helped by Roche collaboration](https://longbridge.com/en/news/295526780.md) - [C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update](https://longbridge.com/en/news/280835753.md) - [Antero Midstream (AM) Misses On Earnings, Is The Stock Fully Priced?](https://longbridge.com/en/news/297431776.md) - [A decade of profitability provides foundation for CLINUVEL’s U.S. expansion | CUVL Stock News](https://longbridge.com/en/news/297129325.md) - [REG - L&G – Asset Mgmt. Ld Prologis, Inc. - Form 8.3 - Prologis, Inc.](https://longbridge.com/en/news/297175228.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**